Assisted Reproductive Technology Market
Industry: Healthcare
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Report Type: Ongoing
Report ID: PMRREP34642
The assisted reproductive technology market is estimated to reach a valuation of US$58.5 Bn by the year 2031, at a CAGR of 9.2%, during the forecast period 2024 to 2031.
Key Highlights of the Market
|
Attributes |
Key Insights |
|
Market Value (2024) |
US$28.4 Bn |
|
Market Size (2031) |
US$58.5 Bn |
|
Forecast Growth Rate (CAGR 2024 to 2031) |
9.2% |
|
Historical Growth Rate (CAGR 2019 to 2023) |
6.5% |
Fertility issues or an inability to conceive children are addressed using Assisted Reproductive Technology (ART), a medical procedure. The manipulation of eggs, sperm, or embryos is a component of ART treatments that enhance the likelihood of a successful and secure pregnancy and the likelihood of conception.
The operation is time-consuming, costly, and extremely invasive. Surgery, hormone therapy, artificial insemination, and intracytoplasmic sperm injection are among the treatment options for male infertility.
The most prevalent ART procedure is in vitro fertilization (IVF), which entails the fertilization of an egg with a sperm in a laboratory setting, followed by the transfer of the resulting embryo to the uterus.
Age, type of procedure, and the extent or cause of infertility are all factors that contribute to the efficacy of ART. The global assisted reproductive technology market share is being driven by the increase in cases of infertility and the advancements in ART research.
From 2019 to 2023, the global assisted reproductive technology (ART) market has undergone substantial growth and transformation, which can be attributed to breakthroughs in technology, rising rates of infertility, and the increasing global acceptance of ART techniques.
The progress in Assisted Reproductive Technology (ART) methods and technology has played a crucial role in broadening market capacities and enhancing the rates of success.
The market expansion has been driven by advancements in treatment outcomes, facilitated by innovations such as preimplantation genetic testing (PGT), embryo cryopreservation procedures, and advanced sperm selection methods.
From a geographical standpoint, North America and Europe have traditionally held a dominant position in the ART industry, which is mostly attributed to their greater levels of healthcare expenditure, favorable regulatory frameworks, and advanced healthcare infrastructure.
Nevertheless, notable expansion has also been witnessed in developing economies throughout Asia Pacific, Latin America, and the Middle East. The accessibility to ART treatments in these places has been increasing due to the improvement of healthcare facilities and the growing awareness.
Although the ART market is experiencing overall good expansion, it encounters obstacles such as expensive treatment expenses, ethical dilemmas, and fluctuating success rates.
Nevertheless, the continuous investigation into reproductive technologies, together with growing investments in healthcare infrastructure, offers substantial prospects for market growth in the foreseeable future.
From 2019 to 2023, the global ART market experienced significant growth, witnessing a CAGR of 6.5% and development due to technical innovations, demographic trends, and regulatory advancements.
In the future, the market is expected to grow further as healthcare providers and stakeholders work towards meeting changing patient needs and improving treatment results.
Rise in Prevalence of Infertility Globally
The rising incidence of infertility, particularly in nations such as China, the US, the UK, and India, is anticipated to drive the assisted reproductive technology market demand.
Based on data published by the National Survey of Family Growth (NSFG), around 7% of women aged 15 to 44 in the United States experienced infertility.
Moreover, there is a greater occurrence of infertility among men worldwide, which is expected to contribute to the expansion of the fertility services industry.
According to research published in the Oxford Journals, approximately 10% of men in the UK between the ages of 16 and 74 have encountered infertility.
The increasing prevalence of infertility can be attributed to the move towards a sedentary lifestyle, elevated stress levels, and increased obesity rates among the general population. Consequently, the need for ART technologies is anticipated to increase globally.
Further, governments and non-profit organizations in developed and emerging nations are actively engaged in providing help to the general people, with the goal of making fertility treatments more accessible. Therefore, these initiatives are expected to stimulate the assisted reproductive technology market growth over the forecast period.
Growing R&D in Fertility Treatment
Progress in fertility treatments encompasses a wide range of choices, including pharmaceutical interventions, surgical procedures, and sophisticated technical alternatives, including cryopreservation of eggs or embryos and artificial insemination.
According to a report released by the National Centre for Biotechnology Information, the success rates of in vitro fertilization (IVF) have remained unchanged at 30% for several years.
Researchers suggest that the implementation of Artificial Intelligence (AI) could enhance these figures. The implementation of artificial intelligence (AI) in clinics can aid practitioners in evaluating the health of embryos and gametes with greater precision and impartiality using picture categorization.
Artificial intelligence can assist doctors in developing a customized treatment strategy for couples. Artificial intelligence (AI) powered image-processing systems can assist in the identification of embryos that have the highest likelihood of successful implantation. AI incorporation into fertility therapies is thus anticipated to stimulate the growth of the assisted reproductive technology market over the forecast period.
Expensive ART Procedures
The costs associated with Assisted Reproductive Technology (ART) can rapidly accumulate, rendering it financially unattainable for certain people and couples.
The high expense of ART is primarily due to the requirement for sophisticated medical equipment, laboratory processes, and highly skilled workers.
Furthermore, the expenses associated with pharmaceuticals used in Assisted Reproductive Technology (ART) can be significant, particularly for hormone therapy that is necessary to induce ovulation.
The strain of assisted reproductive technology expenses might be intensified by the uncertainty of its effectiveness, necessitating many treatment cycles and incurring additional expenses before attaining a successful pregnancy.
Further, the exorbitant expense of assisted reproductive technology operations continues to be a significant obstacle for several individuals and couples who are in search of infertility treatment.
High Health Risks
Assisted Reproductive Technology (ART) methods entail potential health concerns for both the mother and the child, which should be thoroughly evaluated before proceeding with the therapy.
ART carries a significant risk of multiple pregnancies, which can lead to complications like early birth, low birth weight, and various health problems for both the mother and the infants.
Women who undertake assisted reproductive technology operations are at risk of developing ovarian hyper stimulation syndrome (OHSS), a condition characterized by the enlargement and discomfort of the ovaries.
Although OHSS typically presents as a moderate condition, it can result in severe complications, including the accumulation of fluid in the abdomen and chest, the formation of blood clots, and the failure of the kidneys. Assisted reproductive technology, although used to cure infertility, poses possible health hazards that can be a hurdle for the market.
Increased Awareness
There has been a substantial surge in awareness regarding infertility therapies, leading to a greater number of individuals and couples actively seeking remedies to overcome fertility obstacles.
The increasing recognition of this phenomenon has been followed by a change in social perspectives towards Assisted Reproductive Technology, with greater acceptance and comprehension of these interventions as feasible alternatives for attaining pregnancy. Furthermore, there has been a significant rise in the number of couples pursuing assisted reproductive technology operations.
The acknowledgement of male infertility as a substantial contributor to couples' reproductive challenges has intensified the focus on investigating and creating novel therapies for male factor infertility, thereby broadening the scope of potential market prospects and eventually aiding the market share.
IVF Technique Leads the Way with 80% Market Share
|
Market Segment by Technique |
Market Value Share 2023 |
|
IVF |
80% |
Based on the technique segmentation, the assisted reproductive technology market is further segmented into IVF and artificial insemination, where the IVF segment dominates the market share, owing to its high procedural success rate and continuous advancements that satisfy the demand of patients.
Previously, sperm were introduced via injection to enhance the efficacy of in vitro fertilization (IVF). Currently, a time-lapse imaging technique is utilized to capture an image of the egg division.
Therefore, the development of sophisticated technologies in IVF treatment is expected to drive the adoption of fertility services in the market throughout the forecast period.
Fertility Clinics Account for 70% of Total Demand
|
Market Segment by End Use |
Market Value Share 2023 |
|
Fertility Clinics |
70% |
Based on the end use, the market is further classified into fertility clinics and hospitals, where the fertility clinics segment dominates the market with around 70% of the market share.
The fertility clinics segment is expected to continue expanding at the highest growth rate, maintaining its position as the leading industry during the projection period.
The significant assisted reproductive technology market share and accelerated expansion can be ascribed to an increase in the prevalence of infertility cases and the demand for a dedicated facility to carry out assisted reproductive technology.
Furthermore, the growth of this segment is expected to be driven by factors such as cost-effectiveness, specialization, knowledge in the field, and personalized therapy throughout the projected time.
Also, the end-use segment of hospitals, and other settings is projected to experience significant growth in low and middle-income countries due to inadequate infrastructure for establishing fertility clinics. As a result, multispecialty hospitals have emerged as the most accessible choice for infertility treatment.
Europe dominates with 36% of the global ART market share
|
Region |
Market Value Share 2023 |
|
Europe |
36% |
Europe held a dominant position in the market and had the highest revenue share, surpassing 36%. The significant proportion can be ascribed to an increase in the rate of infertility, heightened awareness of fertility treatments, developments in technology, and government activities that provide support.
According to the European Society of Human Reproduction and Embryology, almost 25 million people in the European Union are experiencing infertility, making it the highest rate worldwide.
North America is projected to experience substantial growth throughout the projection period. The rise is ascribed to the favorable results observed in patients undergoing the treatment.
According to reports, around 2.1% of infants in the US are born with the assistance of assisted reproductive technology. The market in Asia Pacific is anticipated to experience growth because of technological improvements and growing research in the field of assisted reproductive technology (ART).
According to a publication in the Reproductive Medicine and Biology Journal, Japan conducted around 458,101 cycles of assisted reproductive technology (ART), resulting in the delivery of approximately 60,598 newborns.
January 2024
Ivy Fertility signed a partnership deal with SMP Pharmacy Solutions to improve the patient experience throughout Ivy's 13 reproductive locations.
February 2023
Bumrungrad International Hospital launched its Fertility Center & IVF Clinic to provide holistic reproductive care, from consultation to assisted reproductive technology treatment and ART care, for families wanting to conceive through the help of technology.
October 2023
Hamilton Thorne Ltd. signed an acquisition deal with Genetics Medical Products and Genetics Services, a leading manufacturer of a diverse array of innovative IVF devices in the global assisted reproductive technology market.
The global market is competitive with several leading IVF treatment clinics and hospitals are providing better commercial offers to their end consumers while offering them with the best infertility solutions while utilizing new and high-end technologies into the assistive reproductive technology.
Major assisted reproductive technology market companies are utilizing high-end technologies to cater to the growing infertility needs of families and cater to their problems with the best of kind fertility solutions.
|
Attributes |
Details |
|
Forecast Period |
2024 - 2031 |
|
Historical Data Available for |
2019 - 2023 |
|
Market Analysis |
US$ Billion for Value |
|
Key Regions Covered |
|
|
Key Companies Profiled |
|
|
Pricing |
Available upon request |
By Technique
By Procedure
By End Use
By Region
To know more about delivery timeline for this report Contact Sales
The market is estimated to exhibit a CAGR of 9.2% during the forecast period.
Europe is the leading region in the market.
The market is segmented based on technique, procedure and end use.
Cryolab Ltd., Vitrolife AB, European Sperm Bank, Bloom IVF Centre, and Merck KGaA are some of the major key companies in the market.
Fertility clinics are the dominant end use segment.
